Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 4.2
edited by manuelmenendez
on 2025/01/27 22:57
on 2025/01/27 22:57
Change comment:
There is no comment for this version
To version 27.1
edited by manuelmenendez
on 2025/01/29 18:48
on 2025/01/29 18:48
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
-
Attachments (0 modified, 1 added, 0 removed)
-
Objects (1 modified, 2 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,9 +2,10 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= Neurodiagnoses =5 += //A new tridimensional diagnostic framework for CNS diseases// = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool. 7 +This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 +We aim to create a structured, interpretable, and scalable diagnostic tool. 8 8 ))) 9 9 ))) 10 10 ... ... @@ -12,18 +12,78 @@ 12 12 ((( 13 13 (% class="col-xs-12 col-sm-8" %) 14 14 ((( 15 -= What can I find here? = 16 += What is this about and what can I find here? = 16 16 17 -* `/docs`: Documentation and contribution guidelines. 18 -* `/code`: Machine learning pipelines and scripts. 19 -* `/data`: Sample datasets for testing. - `/outputs`: Generated models, visualizations, and reports. 18 += **Overview** = 20 20 21 - = Whohas access?=20 +The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: 22 22 22 +* **Axis 1**: Etiology (genetic or other causes of diseases). 23 +* **Axis 2**: Molecular Markers (biomarkers). 24 +* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 25 + 26 +This methodology enables: 27 + 28 +* Greater precision in diagnosis. 29 +* Integration of incomplete datasets using AI-driven probabilistic modeling. 30 +* Stratification of patients for personalized treatment. 31 + 32 +== **The case of neurodegenerative diseases** == 33 + 34 +There have been described these 3 diagnostic axes: 35 + 36 +[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] 37 + 38 +* ((( 39 +**Axis 1: Etiology** 40 + 41 +* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 42 +* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 43 +* //Tests//: Genetic testing, lifestyle, and cardiovascular screening. 44 +))) 45 +* ((( 46 +**Axis 2: Molecular Markers** 47 + 48 +* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. 49 +* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. 50 +* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). 51 +))) 52 +* ((( 53 +**Axis 3: Neuroanatomoclinical** 54 + 55 +* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. 56 +* //Examples//: Hippocampal atrophy correlating with memory deficits. 57 +* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. 58 +))) 59 + 60 +== **Applications** == 61 + 62 +This system enhances: 63 + 64 +* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials. 65 +* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. 66 + 67 +== Who has access? == 68 + 23 23 We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 70 + 71 +== How to Contribute == 72 + 73 +* Access the `/docs` folder for guidelines. 74 +* Use `/code` for the latest AI pipelines. 75 +* Share feedback and ideas in the wiki discussion pages. 76 + 77 +== Key Objectives == 78 + 79 +* Develop interpretable AI models for diagnosis and progression tracking. 80 +* Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. 81 +* Foster collaboration among neuroscientists, AI researchers, and clinicians. 24 24 ))) 25 25 26 26 85 + 86 + 87 + 27 27 (% class="col-xs-12 col-sm-4" %) 28 28 ((( 29 29 {{box title="**Contents**"}} ... ... @@ -30,6 +30,14 @@ 30 30 {{toc/}} 31 31 {{/box}} 32 32 33 - 94 +== Main contents == 95 + 96 +* `/docs`: Documentation and contribution guidelines. 97 +* `/code`: Machine learning pipelines and scripts. 98 +* `/data`: Sample datasets for testing. 99 +* `/outputs`: Generated models, visualizations, and reports. 100 +* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] 101 +* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] 102 +* [[to-do-list>>to-do-list]] 34 34 ))) 35 35 )))
- tridimensional.png
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.manuelmenendez - Size
-
... ... @@ -1,0 +1,1 @@ 1 +149.8 KB - Content
- Collaboratory.Apps.Collab.Code.CollabClass[0]
-
- Public
-
... ... @@ -1,1 +1,1 @@ 1 - No1 +Yes
- XWiki.XWikiRights[3]
-
- Allow/Deny
-
... ... @@ -1,0 +1,1 @@ 1 +Allow - Levels
-
... ... @@ -1,0 +1,1 @@ 1 +view - Users
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.XWikiGuest
- XWiki.XWikiRights[4]
-
- Allow/Deny
-
... ... @@ -1,0 +1,1 @@ 1 +Allow - Groups
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.XWikiAllGroup - Levels
-
... ... @@ -1,0 +1,1 @@ 1 +view